Articles On MGC Pharmaceuticals (ASX:MXC)

The company is confident of a continued increasing trend of MGC Pharma unit sales and new patient growth into 2021.

The company is focused on its core business of executing its growth strategy and become a world-leading, vertically integrated, biopharma company focused on the development and production of phytocannabinoid derived medications for targeted...

The company is focused on its core business of executing its growth strategy and become a world-leading, vertically integrated, biopharma company focused on the development and production of phytocannabinoid derived medications for targeted...

The new sales director has held senior sales and business development positions at multi-national healthcare companies.

The proposed European Union GMP-compliant facility will be able to produce 10,000 units of liquid dose medicines per day and will create a European manufacturing hub for ArtemiC™ with the ability to scale production.

Shares in ASX-listed MGC Pharmaceuticals shot out of the blocks in opening trades on Tuesday following news that the company’s Phase 2 Clinical trial of its ArtemiC anti-inflammatory formulation had achieved a 100 per cent success rate in a...

At the time of writing, the share price of MGC Pharmaceuticals Ltd [ASX:MXC] is flat, trading at 3.2 cents a share. After a slide that persisted through to December, the MXC share price subsequently rose sharply this month... The post MGC P...

Summary EU biopharma player MGC Pharmaceuticals completed Phase II clinical trial of ArtemiCTM in COVID-19 patients. MGC Pharma said the trial met all the requirements of FDA for a COVID-19 study. The Company is planning for an immedi...

Biopharma company MGC Pharmaceuticals (ASX:MXC) has confirmed the successful results of its second phase clinical trial for its anti-inflammatory medicine ... Read More The post MGC Pharmaceuticals confirms Phase II trial success for anti-i...

ASX-listed medicinal cannabis player, MGC Pharmaceuticals, expects results in the next few days from a phase two clinical trial evaluating the safety and efficacy of its natural anti-inflammatory formulation ArtemiC on 50 patients infected...

In anticipation of the trial results, the company is working on the reclassification of ArtemiC from a pharmaceutical product to an investigation medicinal product.

The company's flagship phytomedicines will now have far fewer obstacles to overcome as they work towards market authorisation, registration and patient access.

The company will use the funds from the sale as working capital to fund its core strategy to be a fully vertically integrated, biopharma company.

New joint company secretary Narelle Warren has coordinated and assisted in numerous corporate transactions through private and public equity markets.

The drawdown will be provided through the issue of 3.85 million convertible notes with a face value of A$1 each to Mercer Street Global Opportunity Fund LLC.

Since 2019, Medicinal Cannabis Clinics has facilitated over 4,000 medical consultations with pre-screened eligible patients and has shown continued month-on-month growth.

ASX-listed MGC Pharmaceuticals has received more successful results from its proprietary medical research program aiming to develop a breakthrough cannabis-based treatment for one of the most lethal forms of brain cancer, known as glioblast...

ASX-listed MGC Pharmaceuticals has received more successful results from its proprietary medical research program aiming to develop a breakthrough cannabis-based treatment for one of the most lethal forms of brain cancer, known as glioblast...

The company has developed a formulation of cannabidiol and cannabigerol that is proving effective in inhibiting glioblastoma cells in a pre-clinical research program.

As the second wave of Coronavirus cases continue to wash across the globe, MGC Pharmaceuticals has just completed a Phase 2 clinical trial of its “ArtemiC” natural, anti-inflammatory formulation, on fifty COVID-19-infected patients in Israe...

As the second wave of Coronavirus cases continue to wash across the globe, MGC Pharmaceuticals has just completed a Phase 2 clinical trial of its “ArtemiC” natural, anti-inflammatory formulation, on fifty COVID-19-infected patients in Israe...

The European-based biopharma company believes positive trial results have the potential to deliver material commercial supply opportunities for ArtemiC immediately as a food supplement.

Summary Therapeutic Goods Administration (TGA) has decided to alter the present Poisons Standard to down schedule cannabidiol to make it more accessible via a new Schedule 3 entry. MGC Pharmaceuticals reported over 65% growth in sales s...

ASX-listed and medicinal marijuana group, MGC Pharmaceuticals, has achieved record weekly sales growth of its Mercury Pharma medicinal marijuana product line after breaking into the Australian and Brazilian markets, delivering a 65 per cent...

Is the pot stock boom back? That is the question that investors need to be asking themselves right now. As the sector both locally and abroad is seeing some noteworthy movement. Today, MGC Pharmaceuticals Ltd [ASX:MXC] was busy making their...

It is well on track to achieving record sales for the December quarter with strong domestic order pipeline until the end of 2020 and increasing orders from Brazil and the UK.

Second-stage safety and toxicity tests for MGC Pharmaceuticals’ (ASX:MXC) anti-inflammatory cannabinoid medical spray reveal no adverse effects. ... Read More The post MGC Pharma’s cannabinoid medical spray passes pre-clinical FDA tests app...

Results provide critical additional information on the toxicological evaluation of ArtemiC regarding its effect on organs that were studied and augment base data supporting the current Phase IIa clinical trial on COVID-19 patients and futur...

Medicinal marijuana group, MGC Pharmaceuticals, has successfully shipped its first tetrahydrocannabinol, or “THC” line of Mercury Pharma products to Brazil through its supply agreement with Sao Paulo-based ONIX group.

MGC Pharmaceuticals (ASX:MXC) has shipped its Mercury Pharma THC cannabinoid products to Brazil for the first time under the South ... Read More The post MGC Pharma ships first Mercury Pharma THC products to Brazil appeared first on Stockhe...

Brazil is a strategically important market with a population of over 210 million and a pharmaceutical market value of around A$24 billion per annum, with new patients registering daily for MGC Pharma products after the first week.

Medicinal marijuana group, MGC Pharmaceuticals, has launched a patient information app for its epilepsy medicine CannEpil that it hopes will collect data on a scale that delivers comprehensive and transparent information on medicinal cannab...

At the time of writing, shares of MGC Pharmaceuticals Ltd [ASX:MXC] are up 4.55% to trade at 2.3 cents. The cannabinoid-based pharmaceuticals company recently announced the launch of a new app: CannEpil... The post MGC Pharmaceuticals Shar...

The app will record patient responses to medical questionnaires and the treating practitioner will be able to view the responses in real-time to evaluate the usage, dosage and efficacy of CannEpil®.

The number of new patients trying medicinal cannabis for the first time has risen significantly since Australians first began hunkering down at home to ride out the COVID-19 storm. According to statistics released by the Therapeutics Goods...

As the second wave of Coronavirus cases grips the world, MGC Pharmaceuticals is expanding the Phase 2 clinical trial of its “ArtemiC” natural supplement, designed to treat COVID-19-infected patients, to include an additional site in Israel...

The company recently announced the interim results of the trial met all primary endpoints for the safety and efficacy of the treatment on the first 10 patients in Israel - these interim results also met the FDA primary endpoint.

MGC Pharmaceuticals (ASX:MXC) says it has recruited 33 of the 50 COVID-19  patients it needs for its Phase 2 clinical trial ... Read More The post COVID-19 patients recruited for MGC Pharma’s treatment appeared first on Stockhead.

ASX-listed MGC Pharmaceuticals’ hopes of becoming one of the first medicinal marijuana companies to list on the London Stock Exchange have received a shot in the arm after the UK’s financial markets and services regulator clarified its appr...

The company has welcomed a new guidance note from the FCA and is confident it meets the requirements for LSE listing.

The Australian operations of MGC Pharmaceuticals have been given a potential boost following the recent move by the Therapeutic Goods Administration to allow certain low-dose medicinal cannabis products to be dispensed over the counter by c...

The Therapeutic Goods Administration has confirmed its intention to down schedule certain low-dose medicinal cannabidiol products from Schedule 4 to Schedule 3 status.

ASX-listed MGC Pharmaceuticals has struck a significant funding deal with US-based investment group, Mercer Street Global Opportunity Fund, that allows the medicinal marijuana company to draw on a financing facility of up to $15 million to...

The first tranche of the $2.25 million financing will be provided shortly through the issue of 2,475,000 convertible notes with a face value of $1 each to Mercer Street Global Opportunity.

ASX cannabis stocks are continuing their victory lap following yesterday’s decision by the TGA to re-classify low-dose cannabidiol (CBD) products. The TGA has made an interim decision to down schedule CBD products, including oil and pills,...

A US investment group has agreed to provide medical cannabis company MGC Pharmaceuticals (ASX:MXC) with an initial $2.25m cash injection, and there is the possibility of further funding. Mercer Street Global Opportunity Fund will provide th...

The halt will remain in place until the start of trading on Thursday, September 10, or when an announcement is released to the market

European biopharma company MGC Pharmaceuticals (ASX:MXC) has bolstered its team of directors with the appointment of Evan Hayes, a 20-year expert of the healthcare and biotech sector. Hayes has been appointed as an independent non-executive...

The new appointments ensure the company is well-placed to deliver on its strategy to become a leading manufacturer of high-quality, EU GMP phytocannabinoid-derived medicine products.